Accept Refuse

EUR-Lex Access to European Union law

This document is an excerpt from the EUR-Lex website

Document 32004R1876

Commission Regulation (EC) No 1876/2004 of 28 October 2004 amending Annex I of Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines

OJ L 326, 29.10.2004, p. 22–24 (ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, NL, PL, PT, SK, SL, FI, SV)
OJ L 183M , 5.7.2006, p. 280–282 (MT)
Special edition in Bulgarian: Chapter 11 Volume 036 P. 201 - 203
Special edition in Romanian: Chapter 11 Volume 036 P. 201 - 203
Special edition in Croatian: Chapter 11 Volume 115 P. 197 - 199

No longer in force, Date of end of validity: 12/06/2016; Implicitly repealed by 32016R0793

ELI: http://data.europa.eu/eli/reg/2004/1876/oj

29.10.2004   

EN

Official Journal of the European Union

L 326/22


COMMISSION REGULATION (EC) No 1876/2004

of 28 October 2004

amending Annex I of Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Regulation (EC) No 953/2003 of 26 May 2003 to avoid trade diversion into the European Union of certain key medicines (1), and in particular Article 4(8) thereof,

Whereas:

(1)

The Commission has received applications under Article 4 of Regulation (EC) No 953/2003 with respect to certain pharmaceutical products.

(2)

The Commission has determined that the applications received fulfil the requirements set out in Regulation (EC) No 953/2003 in accordance with the procedure laid down in Article 5(2) of that Regulation.

(3)

The applicants have been informed of the Commission decision to accept their applications.

(4)

It is therefore necessary to add the products concerned to Annex I to Regulation (EC) No 953/2003,

HAS ADOPTED THIS REGULATION:

Article 1

The products and other details mentioned in the Annex to this Regulation shall be added to Annex I to Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines.

Article 2

This regulation enters into force on the day following its publication in the Official Journal of the European Union.

It shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 28 October 2004.

For the Commission

Pascal LAMY

Member of the Commission


(1)  OJ L 135, 3.6.2003, p. 5.


ANNEX

Product

Manufacturer/exporter

Country of destination

Distinctive features

Date of approval

CN/TARIC code (1)

TRIZIVIR

750 mg × 60

Glaxo Smith Kline,

GSK House,

980 Great West Road,

Brentford, Middlesex,

TW8 9GS,

United Kingdom

Afghanistan

Angola

Armenia

Azerbaijan

Bangladesh

Benin

Bhutan

Botswana

Burkina Faso

Burundi

Cambodia

Cameroon

Cape Verde

Central African Republic

Chad

Comoros

Congo

Côte d’Ivoire

Djibouti

DR Congo

East Timor

Equatorial Guinea

Eritrea

Ethiopia

Gambia

Ghana

Guinea

Guinea Bissau

Haiti

Honduras

India

Indonesia

Kenya

Kiribati

Korea (Dem Rep)

Kyrgyz Republic

Lao People’s DR

Lesotho

Liberia

Madagascar

Malawi

Maldives

Mali

Mauritania

Moldova

Mongolia

Mozambique

Myanmar

Namibia

Nepal

Nicaragua

Niger

Nigeria

Pakistan

Rwanda

Samoa

Sao Tome and Principe

Senegal

Sierra Leone

Solomon Islands

Distinctive access pack — trilingual text

19.4.2004

3004 90 19

EPIVIR

150 mg × 60

Glaxo Smith Kline,

GSK House,

980 Great West Road,

Brentford, Middlesex,

TW8 9GS,

United Kingdom

Distinctive access pack — trilingual text

19.4.2004

3004 90 19

RETROVIR

250 mg × 40

Glaxo Smith Kline,

GSK House,

980 Great West Road,

Brentford, Middlesex,

TW8 9GS,

United Kingdom

General export pack (blue) not used in EU

French hospital pack — Francophone markets

19.4.2004

3004 90 19

RETROVIR

300 mg × 60

Glaxo Smith Kline,

GSK House,

980 Great West Road,

Brentford, Middlesex,

TW8 9GS,

United Kingdom

General export pack (blue) not used in EU

French hospital pack — Francophone markets

19.4.2004

3004 90 19

RETROVIR

100 mg × 100

Glaxo Smith Kline,

GSK House,

980 Great West Road,

Brentford, Middlesex,

TW8 9GS,

United Kingdom

General export pack (blue) not used in EU

French hospital pack — Francophone markets

19.4.2004

3004 90 19

COMBIVIR

300/150 mg × 60

Glaxo Smith Kline,

GSK House,

980 Great West Road,

Brentford, Middlesex,

TW8 9GS,

United Kingdom

Distinctive access pack — trilingual text

Bottle (rather than blister pack) “A22” embossed tablets

19.4.2004

3004 90 19

EPIVIR ORAL SOLUTION

10 mg/ml 240 ml

Glaxo Smith Kline,

GSK House,

980 Great West Road,

Brentford, Middlesex,

TW8 9GS,

United Kingdom

Distinctive access pack — trilingual text

19.4.2004

3004 90 19

ZIAGEN

300 mg × 60

Glaxo Smith Kline,

GSK House,

980 Great West Road,

Brentford, Middlesex,

TW8 9GS,

United Kingdom

Somalia

South Africa

Sudan

Swaziland

Tajikistan

Tanzania

Togo

Tuvalu

Uganda

Vanuatu

Yemen

Zambia

Zimbabwe

General export pack — not used in EU

French hospital pack — Francophone countries

20.9.2004

3004 90 19

RETROVIR ORAL SOLUTION

10 mg/ml

200 ml

Glaxo Smith Kline,

GSK House,

980 Great West Road,

Brentford, Middlesex,

TW8 9GS,

United Kingdom

Distinctive access pack — trilingual text

20.9.2004

3004 90 19


(1)  Only if applicable.’


Top